Compare Enveric Biosciences Inc (ENVB) vs iShares 0 3 Month Treasury Bond ETF (SGOV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs iShares 0 3 Month Treasury Bond ETF — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while iShares 0 3 Month Treasury Bond ETF trades at $100.51 (market cap $114.04B). The key difference: iShares 0 3 Month Treasury Bond ETF is far larger — about 17046.3× Enveric Biosciences Inc's market cap, and iShares 0 3 Month Treasury Bond ETF is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and iShares 0 3 Month Treasury Bond ETF for 50 Days on average.
| ENVB | SGOV | |
|---|---|---|
Market Cap | $6.69M | $114.04B |
Volume | 41,141 | 19,563,576 |
Sector | Health | Fixed Income |
52-Week High | $10.80 | $100.72 |
52-Week Low | $1.27 | $100.28 |
Typical Hold Time | 14 Days | 50 Days |
Enterprise Value | -$1.60M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
SGOV (iShares 0-3 Month Treasury Bond ETF) trades at $100.465 with minimal daily movement, reflecting its stable Treasury bill focus. The ETF shows bearish technical signals with 17 sell indicators versus 4 buys, though RSI levels suggest potential oversold conditions. Recent institutional selling by Envestnet Asset Management (-13.2% in Q2 2026) contrasts with consistent dividend distributions around $0.30-0.31 monthly.
SGOV provides stable income exposure to short-term US Treasuries amid rising bond yields, but faces headwinds from the ongoing bond market rout. The ETF's defensive positioning appeals to income-focused investors, though continued yield increases could pressure near-term performance. Current technical weakness suggests cautious entry points may emerge.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About iShares 0 3 Month Treasury Bond ETF
SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →
